An Australian-developed coronavirus vaccine has shown the promising results in pre-clinical testing, raising hopes for its possible effectiveness and manufacturability.
The University Of Queensland released the detailed results of animal trials of its vaccine candidate on 24th August to the International Society for Vaccines, reported Xinhua news agency.
University Of Queensland’s “Molecular Clamp” vaccine works by locking on to the normally unstable, perfusion proteins on the surface of the virus, allowing the body’s immune system to respond more effectively.
“The neutralizing immune response created by our molecular clamp vaccine in animal models was better than the average level of antibodies found in patients who have recovered from Covid-19,” said Keith Chappell, Project co-leader Associate Professor.
In July, Phase one of human trials for the drug commenced in Australia, prior to the existing pre-clinical trial results being made public.
Chappell said that if everything proceeded as planned, large-scale manufacturing efficacy assessments could move forward before the end of the year.
“One of the big challenges in the development of vaccines is the ability to produce them at sufficient scale for widespread use,” explained Chappell.
UQ revealed an agreement with Australian biotechnology giant CSL in June to locally manufacture millions of doses of the vaccine should it continue to prove viable throughout the rest of the trial process.
A vaccine was vital for putting an end to the pandemic and the team from UQ were committed to sharing their data and comparing it to the international reference standard, said Kate Jones, Queensland Innovation Minister.
“From the outset we’ve been clear that we are racing against the virus and not against other projects, and now more than ever it is important for the scientific world to work together,” said Jones.